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Abstract
3',5'-Cyclic	nucleotide	phosphodiesterases	(PDEs,	3',5'-cyclic-nucleotide	5'-nucleotidohydrolase),	E.C.
3.1.4.17,	catalyse	the	hydrolysis	of	a	3',5'-cyclic	nucleotide	(usually	cyclic	AMP	or	cyclic	GMP).
isobutylmethylxanthine	is	a	nonselective	inhibitor	with	an	IC50	value	in	the	millimolar	range	for	all
isoforms	except	PDE	8A,	8B	and	9A.	A	2',3'-cyclic	nucleotide	3'-phosphodiesterase	(E.C.	3.1.4.37
CNPase)	activity	is	associated	with	myelin	formation	in	the	development	of	the	CNS.
Contents
This	is	a	citation	summary	for	Phosphodiesterases,	3',5'-cyclic	nucleotide	(PDEs)	in	the	Guide	to
Pharmacology	database	(GtoPdb).	It	exists	purely	as	an	adjunct	to	the	database	to	facilitate	the
recognition	of	citations	to	and	from	the	database	by	citation	analyzers.	Readers	will	almost	certainly
want	to	visit	the	relevant	sections	of	the	database	which	are	given	here	under	database	links.
GtoPdb	is	an	expert-driven	guide	to	pharmacological	targets	and	the	substances	that	act	on	them.
GtoPdb	is	a	reference	work	which	is	most	usefully	represented	as	an	on-line	database.	As	in	any
publication	this	work	should	be	appropriately	cited,	and	the	papers	it	cites	should	also	be	recognized.
This	document	provides	a	citation	for	the	relevant	parts	of	the	database,	and	also	provides	a
reference	list	for	the	research	cited	by	those	parts.	For	further	details	see	[12].
Please	note	that	the	database	version	for	the	citations	given	in	GtoPdb	are	to	the	most	recent
preceding	version	in	which	the	family	or	its	subfamilies	and	targets	were	substantially	changed.	The
links	below	are	to	the	current	version.	If	you	need	to	consult	the	cited	version,	rather	than	the	most
recent	version,	please	contact	the	GtoPdb	curators.
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